Industry News

• Mayo research: intervention drops hospital infection rate by a third  Clostridium difficile is the one of the leading pathogens causing hospital-acquired infection in the U.S. It may cause diarrhea, colitis, sepsis and lead to prolonged hospitalization and death. Mayo Clinic researchers say they've found a way to reduce the acquisition of this infection.
  Mayo Clinic March 19, 2010  
• NIH announces genetic testing registry  The National Institutes of Health announced that it is creating a public database that researchers, consumers, health care providers, and others can search for information submitted voluntarily by genetic test providers.
  National Institutes of Health March 18, 2010  
• Jury rules in favour of AstraZeneca in first US Seroquel product liability trial  AstraZeneca announced that a jury in a New Jersey state court in the US ruled in favour of AstraZeneca by rejecting a Louisiana plaintiff's claims that SEROQUEL caused his alleged injuries. The case, Baker v. AstraZeneca, was the first product liability case to go to trial.
  AstraZeneca March 18, 2010  
• FDA approves Envoy Medical 's first totally implanted hearing system   The FDA announced the approval of the Esteem – an implanted hearing system used to treat moderate to severe sensorineural hearing loss, a type of permanent hearing loss. As a condition of FDA approval, Esteem manufacturer, Envoy Medical of St. Paul, Minn., must conduct two post-approval studies.
  U.S. Food and Drug Administration March 18, 2010  
• Drug production gets aquatic  Green algae are cheap to grow, hard to kill, and quick to thrive. Such traits make the tiny plants an ideal production factory, one that is already being extensively explored as a source for biofuels.
  MIT Technology Review March 17, 2010  Lauren Gravitz
• FDA asks consumers to submit questions as part of transparency plan  So how and when does the Food and Drug Administration decide to pull a prescription from the market? Should I be asking whether my doctor accepts gifts or sandwiches from drug companies? Why are drugmakers notified by the FDA when a device is harmful before the general public?
  Chicago Tribune March 17, 2010  Bruce Japsen
• U.S. Food And Drug Administration accepts New Drug Application  Bristol-Myers Squibb and AstraZeneca announced that the FDA has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA(TM) (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets.
  Bristol-Myers Squibb Company March 17, 2010  
• Study shows Prevenar 13* is immunogenic in young children previously vaccinated  According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13* was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar* (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed).
  Pfizer Inc. March 17, 2010  
• BioMS Medical announced financial and operational results  BioMS Medical reported revenue of $45.6 million for the year ended December 31, 2009 compared to $52.6 million for the year ended December 31, 2008, and net income was $2.9 million versus net loss of $(0.5) million for the previous year.
  BioMS Medical Corp. March 16, 2010  
• Boston Scientific completes enrollment in PLATINUM trials  Boston Scientific announced completion of patient enrollment in the Small Vessel and Long Lesion trials of its PLATINUM clinical program that are designed to compare the platinum chromium PROMUS® Element Everolimus-Eluting Stent System to matched historical control groups of patients.
  Boston Scientific Corporation March 16, 2010  

   (next 10 articles)